Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Publishes Data on Cancer of Unknown Primary Origin Test

Premium

Rosetta Genomics last week published data validating its miRview Mets 2 cancer of unknown primary origin diagnostic.

In a paper published in The Oncologist, company researchers reported that the test could use microRNA signatures to identify 42 tumor types with high accuracy, maintaining the performance across patient samples.

“In the study, the assay was first validated on 509 samples of known origin in a blinded manner and demonstrated 85 percent accuracy, with the vast majority of samples resulting in a single reported origin, which was accurate in 90 percent of the cases,” Rosetta said. Clinico-pathologic evaluation validated the performance of the assay in bona fide CUP cases.

The publication comes on the heels of Rosetta's announcement that miRview Mets 2 had received Medicare coverage (GSN 5/17/2012).

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.